This study aims to prospectively explore the real life short and longer term outcomes of Vedolizumab in pediatric inflammatory bowel disease and to develop a prediction model for treatment success based on Vedolizumab trough levels and other clinical and laboratory markers. Children under 18 years of age that have been diagnosed with IBD and their physician is starting treatment with Vedolizumab may be eligible.

For More Information

Contact Us Online

Call 215-590-7801

Related Conditions